azelnidipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 272 123524-52-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • azelnidipine
  • calblock
  • CS-905
  • Molecular weight: 582.66
  • Formula: C33H34N4O6
  • CLOGP: 6.96
  • LIPINSKI: 2
  • HAC: 10
  • HDO: 2
  • TPSA: 137.03
  • ALOGS: -5.85
  • ROTB: 11

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 52.28 27.34 25 1603 34396 46650038
Altered state of consciousness 51.48 27.34 22 1606 23326 46661108
Cerebral infarction 48.18 27.34 21 1607 23345 46661089
Liver disorder 47.46 27.34 24 1604 37222 46647212
Cardiac failure 32.78 27.34 25 1603 79923 46604511
Brain stem haemorrhage 32.43 27.34 7 1621 716 46683718
Platelet count decreased 29.87 27.34 26 1602 99998 46584436
Interstitial lung disease 29.26 27.34 20 1608 53929 46630505

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 79.30 24.33 43 1878 41902 29908655
Cerebral infarction 73.02 24.33 35 1886 26338 29924219
Interstitial lung disease 50.77 24.33 37 1884 60160 29890397
Renal impairment 39.87 24.33 37 1884 84147 29866410
Hyperuricaemia 30.56 24.33 13 1908 7381 29943176
Liver disorder 29.00 24.33 20 1901 29702 29920855
Blood creatine phosphokinase increased 26.16 24.33 22 1899 43826 29906731
Gastric cancer 24.84 24.33 10 1911 4940 29945617

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.74 Basic
pKa2 1.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER DRUG LABEL KEGG DRUG

External reference:

IDSource
PV23P19YUG UNII
D01145 KEGG_DRUG
C0753287 UMLSCUI
CHEBI:31247 CHEBI
CHEMBL1275868 ChEMBL_ID
DB09230 DRUGBANK_ID
65948 PUBCHEM_CID
7109 INN_ID
C061679 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None